Verity Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Verity Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,572	Closed	-$326K	–	145
2019 Q2	$326K	Buy	4,572 +770	+20%	+$56.7K	0.37%	87
2019 Q1	$298K	Buy	3,802 +197	+5%	+$14.9K	0.34%	86
2018 Q4	$305K	Buy	3,605 +822	+30%	+$87.6K	0.41%	68
2018 Q3	$477K	Sell	2,783 -478	-15%	-$72.1K	0.47%	47
2018 Q2	$421K	Sell	3,261 -1,126	-26%	-$126K	0.38%	48
2018 Q1	$452K	Buy	4,387 +216	+5%	+$21.4K	0.41%	45
2017 Q4	$410K	Sell	4,171 -3	-0.1%	-$260	0.31%	54
2017 Q3	$378K	Sell	4,174 -460	-10%	-$36.4K	0.29%	53
2017 Q2	$351K	Buy	4,634 +862	+23%	+$60.3K	0.26%	63
2017 Q1	$249K	Buy	+3,772	New	+$248K	0.21%	87

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Verity Asset Management's LGND Position: Q3 2019 in Review

Verity Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 4,572 shares — an estimated $326K sold.

Verity Asset Management first reported a position in LGND in Q1 2017 and held it in 10 quarters. The position peaked at $477K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Verity Asset Management reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Verity Asset Management sold 4,572 Ligand Pharmaceuticals shares in Q3 2019, an estimated $326K.
Verity Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 10 quarters.
Verity Asset Management's Ligand Pharmaceuticals position peaked at $477K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Verity Asset Management's 13F filing for Q3 2019, filed 1 Nov 2019.